Doliver Advisors LP Has $2.09 Million Position in Abbott Laboratories $ABT

Doliver Advisors LP increased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 14.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,343 shares of the healthcare product maker’s stock after acquiring an additional 1,917 shares during the quarter. Abbott Laboratories comprises 0.6% of Doliver Advisors LP’s portfolio, making the stock its 29th biggest holding. Doliver Advisors LP’s holdings in Abbott Laboratories were worth $2,087,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. First Financial Bank Trust Division boosted its stake in Abbott Laboratories by 0.4% in the 2nd quarter. First Financial Bank Trust Division now owns 103,879 shares of the healthcare product maker’s stock valued at $14,129,000 after purchasing an additional 395 shares during the period. Harbor Investment Advisory LLC grew its holdings in shares of Abbott Laboratories by 0.4% during the 2nd quarter. Harbor Investment Advisory LLC now owns 25,859 shares of the healthcare product maker’s stock worth $3,517,000 after purchasing an additional 98 shares in the last quarter. Kera Capital Partners Inc. grew its holdings in shares of Abbott Laboratories by 11.3% during the 2nd quarter. Kera Capital Partners Inc. now owns 2,583 shares of the healthcare product maker’s stock worth $351,000 after purchasing an additional 262 shares in the last quarter. AG2R LA Mondiale Gestion D Actifs acquired a new stake in shares of Abbott Laboratories during the 1st quarter worth $8,562,000. Finally, Howe & Rusling Inc. grew its holdings in shares of Abbott Laboratories by 6.4% during the 1st quarter. Howe & Rusling Inc. now owns 5,478 shares of the healthcare product maker’s stock worth $727,000 after purchasing an additional 329 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $133.92 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The company has a market cap of $233.08 billion, a P/E ratio of 16.78, a P/E/G ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The business has a fifty day simple moving average of $130.41 and a 200 day simple moving average of $131.32.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. The company had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on ABT shares. Raymond James Financial reduced their target price on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a report on Friday, July 18th. Evercore ISI increased their target price on Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Morgan Stanley upped their price objective on Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Jefferies Financial Group upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and upped their price objective for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. Finally, Wells Fargo & Company dropped their price objective on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research report on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $144.47.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.